BioSpace News Archive

Vallon Pharmaceuticals, Inc today announced topline results from its pivotal SEAL study evaluating ADAIR, a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD).

Compugen Ltd. today announced that it will give a presentation today on exploring the immune-tumor microenvironment (TME) using high resolution single-cell spatial transcriptomics at the Keystone Symposium.

Ionis Pharmaceuticals, Inc. announced that management will present at the following investor conferences.

Aura Biosciences Inc. today announced that the European Commission has granted Orphan Drug Designation to AU-011, its first VDC product candidate, for the treatment of uveal melanoma.

Spok Holdings, Inc. (NASDAQ: SPOK) (“Spok” or the “Company”), a global leader in healthcare communications, today announced that it has reduced the size of its Board of Directors (the “Board”) to six members to better align the Board’s size and composition with the Company’s recently announced business strategy.

We are excited to have Romesh join Ceptur as we advance our broad discovery pipeline based on our proprietary U1 Adaptor technology.

EVUSHELD ™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies.

Diffusion Pharmaceuticals Inc. today announced financial results for 2021 and provided a business update.

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the last patient in its U.S. Phase 2 clinical study of EscharEx® for the debridement of venous leg ulcers (VLUs) has completed the study treatment visits as well as the required follow up.

Crinetics Pharmaceuticals, Inc today announced the appointment of Chris Robillard to the newly created position of chief business officer.